Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial.

There is no improvement in PFS with the nedaplatin and docetaxel combination in the intent-to-treat analysis. More hematological toxicities were observed in the ND group (compared with CD), while more non-hematological toxicities were observed in the CD group. ND could be a new treatment option for advanced or relapsed squamous cell lung cancer.